Topotecan hydrochloride hydrate is an orally active and potentTopoisomeraseIinhibitor. Topotecan hydrochloride hydrate induces cell cycle arrest in G0/G1 and S phases and promotesapoptosis. Topotecan hydrochloride hydrate shows anticancer activity^[1].

Topotecan hydrochloride hydrate obviously inhibits proliferation of human glioma cells and glioma stem cells (GSCs) in a dose- and time-dependent manner^[1].
Topotecan hydrochloride hydrate (0-40 μM) obviously inhibits the cell viability compared with the control groups, in a dose-dependent manner^[1].
Topotecan hydrochloride hydrate shows anti-proliferation activity against U251, U87, GSCs-U251 and GSCs-U87 cells, withIC₅₀values of 2.73±0.25, 2.95±0.23, 5.46±0.41, and 5.95±0.24 μM, respectively^[1].

Topotecan hydrochloride hydrate (0.5, 1.0, and 1.5 mg/kg; Orally, daily) causes greater reduction in microvascular density in an ovarian cancer model, but the mice treated with 1.5 mg/kg daily, oral Topotecan show decreased food intake, and a lesser antitumor effect^[2].

475.92

C₂₃H₂₆ClN₃O₆

1044663-62-8

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.